{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-24-000086","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.378331+00:00","generated_at":"2026-05-30T02:19:24.481966+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biohaven reports Q3 net loss $160.3M; troriluzole SCA trial positive, NDA submission planned Q4 2024","bullets":["Net loss $160.3M ($1.70/sh) vs $102.6M loss ($1.50/sh) in Q3 2023; non-GAAP adj. net loss $164.1M ($1.74/sh).","Cash position $642M as of Oct 2, 2024, including $269.9M net from Oct 2024 public offering of 6.05M shares at $47.50.","Troriluzole met primary endpoint in pivotal SCA trial; NDA submission to FDA on track for Q4 2024.","Initiated Phase 2 trial of BHV-2100 (TRPM3 antagonist) in acute migraine; expects Phase 3 SMA topline data in Q4 2024.","R&D expenses rose to $157.6M from $95.5M YoY due to advancing late-stage trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-24-000086","json":"https://secwatch.observer/filing/0001935979-24-000086.json","markdown":"https://secwatch.observer/filing/0001935979-24-000086.md","text":"https://secwatch.observer/filing/0001935979-24-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/0001935979-24-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/bhvn-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:19:24.481966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}